Want to see HK:2575 full AI Analyst Report?
2575 Stock Chart & Stats
HK$33.56
--
Market closed
HK$33.56
--
Day’s Range― - ―
52-Week RangeHK$10.60 - HK$96.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
HK$5.69B
Enterprise ValueHK$8.25B
Total Cash (Recent Filing)HK$216.62M
Total Debt (Recent Filing)HK$1.37M
Price to Earnings (P/E)―
Beta2.83
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding160,702,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio2.47
Price to Book (P/B)23.93
Price to Sales (P/S)650.34
P/FCF Ratio-163.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Revenue GrowthSustained, large revenue increases across 2024–2025 indicate durable commercial traction and expanding market adoption. Persistent top-line scaling provides the volume base necessary for operating leverage, supports future margin improvement, and reduces single-product concentration risk as the business matures.
Improving Margins (gross Margin Turned Positive)A move to positive gross margin signals improving unit economics and better cost absorption. If maintained, this structural improvement enables scalable profitability as fixed costs spread, making operating leverage achievable and enhancing the prospects for sustainable operating profit as revenue grows further.
Conservative Balance Sheet With Low DebtLow leverage and rising equity/assets through 2025 give the company financial flexibility to fund R&D and commercialization without immediate refinancing pressure. This durable capital structure reduces bankruptcy and solvency risks, supporting multi‑period investment in pipeline and market expansion.
Bears Say
Persistent Operating And Net LossesContinued operating and net losses mean the business has not yet reached self-sustaining profitability, consuming capital and limiting internal funding for growth. Over the medium term this raises execution risk, increases reliance on external financing, and delays shareholder value realization.
Consistent Negative Operating And Free Cash FlowNegative OCF and FCF in every reported year create a structural funding requirement that can force dilution or debt financing. Although burn improved in 2025, failure to convert revenue growth into positive cash flow keeps the company exposed to capital-market cycles and constrains long-term strategic optionality.
Negative Returns On Capital / Execution RiskConsistently negative ROE shows invested capital does not produce positive economic returns, undermining long-term shareholder value creation. Even with a conservative balance sheet, persistent negative returns increase the probability of future funding needs and heighten execution risk if the company cannot sustainably improve margins and cash conversion.
Xuanzhu Biopharmaceutical Co., Ltd. Class H News
2575 FAQ
What was Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Xuanzhu Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$10.60 and its highest was HK$96.90 in the past 12 months.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap is HK$5.69B.
When is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xuanzhu Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Xuanzhu Biopharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Xuanzhu Biopharmaceutical Co., Ltd. Class H pay dividends?
Xuanzhu Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xuanzhu Biopharmaceutical Co., Ltd. Class H have?
Xuanzhu Biopharmaceutical Co., Ltd. Class H has 160,702,000 shares outstanding.
What happened to Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xuanzhu Biopharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xuanzhu Biopharmaceutical Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.47%
Trailing 12-Months
Company Description
Xuanzhu Biopharmaceutical Co., Ltd. Class H
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―